Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.
Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM. Juvekar A, et al. Among authors: wulf gm. Cancer Discov. 2012 Nov;2(11):1048-63. doi: 10.1158/2159-8290.CD-11-0336. Epub 2012 Aug 22. Cancer Discov. 2012. PMID: 22915751 Free PMC article.
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells.
Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG. Israelsen WJ, et al. Among authors: wulf gm. Cell. 2013 Oct 10;155(2):397-409. doi: 10.1016/j.cell.2013.09.025. Cell. 2013. PMID: 24120138 Free PMC article.
Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors.
Emerling BM, Hurov JB, Poulogiannis G, Tsukazawa KS, Choo-Wing R, Wulf GM, Bell EL, Shim HS, Lamia KA, Rameh LE, Bellinger G, Sasaki AT, Asara JM, Yuan X, Bullock A, Denicola GM, Song J, Brown V, Signoretti S, Cantley LC. Emerling BM, et al. Among authors: wulf gm. Cell. 2013 Nov 7;155(4):844-57. doi: 10.1016/j.cell.2013.09.057. Cell. 2013. PMID: 24209622 Free PMC article.
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Juvekar A, Hu H, Yadegarynia S, Lyssiotis CA, Ullas S, Lien EC, Bellinger G, Son J, Hok RC, Seth P, Daly MB, Kim B, Scully R, Asara JM, Cantley LC, Wulf GM. Juvekar A, et al. Among authors: wulf gm. Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4338-47. doi: 10.1073/pnas.1522223113. Epub 2016 Jul 8. Proc Natl Acad Sci U S A. 2016. PMID: 27402769 Free PMC article.
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Matulonis UA, et al. Among authors: wulf gm. Ann Oncol. 2017 Mar 1;28(3):512-518. doi: 10.1093/annonc/mdw672. Ann Oncol. 2017. PMID: 27993796 Free PMC article. Clinical Trial.
94 results